Clinical Trials

    Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) with Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib

    Study Coordinator: Milan Sheth

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06536413

    Phone: 713.790.3311

    Protocol Number: PRO00037762

    Description


    This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM), in patients considered refractory to proteasome inhibitors (PIs). MM is an incurable clonal plasma cell disorder that comprises 10% of all hematologic malignancies.